Salute e Benessere

LTS expands its CDMO capabilities with the acquisition of Renaissance Lakewood

The acquisition of Renaissance marks a significant milestone in LTS's strategy to expand its capabilities in the CDMO space. Renaissance brings deep expertise, state-of-the-art manufacturing infrastructure, and a talented workforce of approximately 500 employees. This move enables LTS to offer a broader range of drug delivery solutions and strengthens its position within the CDMO community. The acquisition of Renaissance marks a significant milestone in LTS's strategy to expand its…
PR Newswire
13/10/2025

CHAPPER healthcare, AscellaHealth’s Global Pharmaceutical Distributor…

This milestone marks half a century of innovation, reliability and access to life-saving medicines worldwide CHAPPER healthcare,AscellaHealth’sglobal pharmaceutical wholesaler, distributor, and service provider, proudly celebrates its 50th anniversary—marking five decades of delivering critical access to licensed and unlicensed medicines to patients in more than 80 countries across six continents. With subsidiaries in Ireland and the United Arab Emirates, and a strategic warehousing hub...
Nasdaq GlobeNewswire
13/10/2025

Zinzino AB (publ.): Pioneering Gut Health Testing With a Simple Finger Prick

Research indicates that a balanced gut supports the whole body. More than 70% of the body's immune system is in the gut, and every gut microbiome is different.¹ Traditional microbiome (stool) tests only look at the diversity of microbes present in the gut. Zinzino's Gut Health Test is the first of a new generation of gut health tests that measure gut function and whether these processes strengthen or strain the immune system.² Individuals can then use the test results to take proactive steps to…
PR Newswire
13/10/2025

Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the…

"This marks another important milestone for us. Following our successful presentation of LNP7457, a PRMT5 inhibitor, at ASCO in June 2025, it is a privilege to present the findings of another Phase 1 clinical trial for LNP3693, a STING agonist, at ESMO. ESMO's acknowledgment of the clinical research conducted in India underscores the proficiency of our team in oncology drug discovery, research, and clinical development," said Vinita Gupta, CEO, Lupin. "This marks another important…
PR Newswire
13/10/2025

Implantica completes FDA 100-Day Meeting for RefluxStop® PMA application

Dr. Peter Forsell, CEO and founder of Implantica, says, "We are very encouraged by the constructive outcome of the FDA 100-Day meeting. The dialogue provided valuable clarity on what FDA requires in the remaining steps in the PMA review process. With this feedback, Implantica now has the necessary insight to finalize the remaining pieces of information that FDA would like to see." Dr.Peter Forsell, CEO and founder of Implantica, says, "We are very encouraged by the constructive…
PR Newswire
13/10/2025

AnnJi Showcases Clinical Breakthrough of AJ201 at WMS 2025

Dr. Andrew Pai presented the latest preclinical research of Rosolutamide (JM17), the active ingredient of AJ201. JM17 demonstrated multi-pathway benefits in SBMA mouse model, including enhanced mitochondrial function, reduced inflammation and fibrosis, as well as improved structural organization of muscle fibers. Upstream regulator analysis further confirmed the inhibition of pro-inflammatory mediators (TNF-α, IL-6, TGF-β) alongside activation of protective signaling pathways. These findings…
PR Newswire
13/10/2025

Cumulus Neuroscience Presents Data at the International Society for CNS Clinical…

The first poster, presented at ECNP, titled, "Deploying User-Friendly Portable EEG to Measure Response to a Novel Antidepressant with Resting and Task-Driven Neurophysiological Endpoints," reported interim data from a Phase1bstudy conducted in partnership with Delix Therapeutics. The poster featured data evaluating the pharmacodynamics, safety, and tolerability of a novel neuroplastogen, DLX-001, in people with MDD. The Phase1bstudy was designed to show early evidence of...
PR Newswire
13/10/2025

POLYTECH Raises Visibility in The Guardian via Awareness Feature on Breast…

In the article, François Franca Franco Junior (POLYTECH's UK & Ireland General Manager) shares insights on how cutting-edge implant technology can improve patient outcomes. The Guardian piece notes that breast reconstruction is not merely cosmetic but "about comfort, confidence and long-term results," emphasizing the importance of informed choice for women after mastectomy. It introduces B-Lite®, the world's first and only lightweight breast implant, which is up to 30% lighter than…
PR Newswire
13/10/2025

Bavarian Nordic shareholders are reminded of expiry of the offer period…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, 13 October 2025– Reference is made to the company announcement dated 26 August 2025 (no. 24/2025) and the company announcement dated 29 September 2025 (no. 27/2025) regarding the all-cash voluntary board-recommended public takeover offer to acquire all of the issued and...
Nasdaq GlobeNewswire
13/10/2025

Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for…

"We are honored that bexicaserin has been granted Breakthrough Therapy Designation, recognizing the potential of our innovative approach to advancing treatment in one of the most challenging areas of epilepsy," said Johan Luthman, EVP and Head of Research & Development at Lundbeck. "Drawing on our expertise in neuroscience, and past experiences with epilepsy therapies, we are deeply committed driving the global Phase 3 clinical program forward. Obtaining BTD for the program in…
PR Newswire
13/10/2025

ISTH marks World Thrombosis Day with urgent global call to action

Observed annually on October 13, World Thrombosis Day underscores the urgent need for early detection and prevention of thrombosis, commonly known as blood clots. Thrombosis contributes to the world's three leading cardiovascular killers: heart attack, stroke and venous thromboembolism (VTE). Yet awareness remains critically low. Each year, an estimated 10 million cases of hospital-associated blood clots occur globally, resulting in up to 100,000 deaths in the United States alone. Many of these…
PR Newswire
13/10/2025

ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accelerating…

Commercial traction : 40 ARC-EX ®Systems were sold in Q3, demonstrating continued strong commercial traction for the Company’s groundbreaking external spinal cord stimulation technology. More than 50 clinics across the US are now equipped with the ARC-EX System.Regulatory milestones : The Company received CE Mark certification for the ARC-EX System, indicated to improve hand strength and sensation after SCI, both in the clinic and at home. Additionally, the US Food and Drug...
Nasdaq GlobeNewswire
13/10/2025

Roche data at ESMO 2025 showcase advances in science and cancer care across…

Key presentations include: Giredestrant: Primary results from the phase III evERA Breast Cancer study, the first positive head-to-head phase III trial investigating a selective oestrogen receptor (ER) degrader-containing regimen versus a standard of care combination in the post-cyclin-dependent kinase inhibitor setting for people with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. 1,2The study met both co-primary...
Nasdaq GlobeNewswire
13/10/2025

Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth…

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlookMännedorf, Switzerland, October 13, 2025 –The Tecan Group (SIX Swiss Exchange: TECN) today provided a qualitative update on its performance for the third quarter of 2025. Sales for the third quarter increased by a mid-single-digit percentage in local...
Nasdaq GlobeNewswire
13/10/2025

EarlyHealth Group Acquires CYB3R, Gulf’s Fastest-Growing Cybersecurity Firm

CYB3R, owned by tech entrepreneurs Alex Halsall and Jack Tupper, has rapidly gained prominence by securing critical infrastructure and sensitive data in regulated industries across the Middle East and Europe. By embedding CYB3R’s capabilities into EarlyHealth’s global platform, the partnership will scale operations internationally and deliver turnkey solutions that safeguard clinical studies, institutional programs, and government initiatives.“With a growing portfolio of 1,200...
Nasdaq GlobeNewswire
12/10/2025

Sandstone Easydrip™ Plus Pen Needles Debut in Turkey -- Patent‑Protected…

Key advantages Key advantages Market relevance As the first pen needle with a patent‑protected hexagonal hub available inTurkey, Easydrip™ Plus is already attracting interest from neighbouring countries and sets a practical alternative between premium global brands and low‑end generics. Availability & next steps Certifications Easydrip™ Plus is manufactured under a strict ISO 13485 quality system and holds CE Declaration of Conformity, meeting international safety...
PR Newswire
11/10/2025

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release…

FDA approves UZEDY ®(risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. 1 UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults. 1 This approval marks a significant step towards addressing the unmet needs of...
Nasdaq GlobeNewswire
10/10/2025

AB Science today reports its revenues for the first half of 2025 and provides an…

PRESS RELEASEAB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2025 AND KEY EVENTS DURING THE PERIOD Financial and corporate situation Operating deficit reduced by 24% compared to the first half of 2024, amounting to €2.7 million as of June 30, 2025Capital increase through private placements for a total amount of €6.3 million Clinical development Masitinib platform: Authorization from several European countries for the confirmatory Phase 3 study...
Nasdaq GlobeNewswire
10/10/2025

Press release: Transparency Notification from Shareholder

Transparency Notification from ShareholderGhent, Belgium – 10 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received transparency notifications in relation to the entities listed below, notifying the number of voting rights attached to the shares mentioned next to their name in the table below…
Nasdaq GlobeNewswire
10/10/2025

Single-use Bioprocessing Market worth US$33.67 billion by 2030 with 13.3% CAGR |…

Browse in-depth TOC on "Single Use Bioprocessing Market" Browse in-depth TOC on "Single Use Bioprocessing Market" 740 - Tables 65 - Figures 570 - Pages Based on region, the single-use bioprocessing market is segmented into six major regions, namelyNorth America,Europe,Asia Pacific,Latin America, theMiddle East, andAfrica. In 2024,North Americadominated the single-use bioprocessing market. Significant spending on pharmaceutical R&D activities,...
PR Newswire
10/10/2025

Global Healthcare and Wellness Market Outlook 2024-2030: CAM, Beauty Care, and…

The global market for Healthcare and Wellness was estimated to be worth USD 5243 Million in 2023 and is forecast to a readjusted size of USD 8419.1 Million by 2030 with a CAGR of 7.0% during the forecast period 2024-2030. The global market for Healthcare and Wellness was estimated to be worthUSD 5243 Millionin 2023 and is forecast to a readjusted size ofUSD 8419.1 Millionby 2030 with a CAGR of 7.0% during the forecast period 2024-2030. Download Free Data What are the key...
PR Newswire
10/10/2025

Global Cigar Humidors Market to Reach $628 Million by 2031, Driven by Luxury and…

The global market for Cigar Humidors was valued at USD 370 Million in the year 2024 and is projected to reach a revised size of USD 628 Million by 2031, growing at a CAGR of 8.0% during the forecast period. The global market for Cigar Humidors was valued atUSD 370 Millionin the year 2024 and is projected to reach a revised size ofUSD 628 Millionby 2031, growing at a CAGR of 8.0% during the forecast period. Download Free Data What are the key factors driving the growth of...
PR Newswire
10/10/2025

Management Rotation at Three MAXIMA GRUPĖ Companies

Management Rotation at Three MAXIMA GRUPĖ CompaniesMAXIMA GRUPĖ announces that, as of 13 October 2025, Jolanta Bivainytė is appointed as CEO of MAXIMA GRUPĖ, Kristupas Buzys – as CEO of MAXIMA LT, UAB and Tomas Bazys – as CEO of FRANMAX, UAB. Jolanta Bivainytė will take over as Chairwoman of the Board and CEO of MAXIMA GRUPĖ on October 13, replacing Manfredas Dargužis. M. Dargužis is appointed as the Head of Expansion of “Vilniaus prekyba“ and will continue to serve as a member of the...
Nasdaq GlobeNewswire
10/10/2025

MAXIMA GRUPĖ Borrows EUR 260 Million from SEB and ING Banks to Redeem Bonds

MAXIMA GRUPĖ Borrows EUR 260 Million from SEB and ING Banks to Redeem BondsMAXIMA GRUPĖ, UAB (hereinafter – MAXIMA GRUPĖ) announces that it has signed a short-term 2-year financing agreement for a total amount of EUR 260 million with Skandinaviska Enskilda Banken AB, AB SEB bankas (together EUR 130 million) and ING Belgium SA/NV (EUR 130 million). The funds received from the banks will be used for the early redemption of the MAXIMA GRUPĖ issued long-term bonds and for its related...
Nasdaq GlobeNewswire
10/10/2025
Altri  Comunicati